Level Biotechnology

Level Biotechnology ROCE

The Return on Capital Employed (ROCE) of Level Biotechnology (3118.TWO) as of Oct 28, 2026 is 14.40 %. In the previous year, Return on Capital Employed (ROCE) was 13.44 % — a change of 7.10% (higher).

ROCE

14.40 %

YoY

7.10%

Last updated:

In 2025, Level Biotechnology's return on capital employed (ROCE) was 14.40 %, a 7.10% increase from the 13.44 % ROCE in the previous year.

The Level Biotechnology ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
9.86 TWD
Jan 1, 2019
10.99 TWD
Jan 1, 2020
13.81 TWD
Jan 1, 2021
15.67 TWD
Jan 1, 2022
13.55 TWD
Jan 1, 2023
14.42 TWD
Jan 1, 2024
13.44 TWD
Jan 1, 2025
14.40 TWD
The Level Biotechnology ROCE history
YEARROCEYoY
14.40 %+7.10%
13.44 %-6.78%
14.42 %+6.39%
13.55 %-13.54%
15.67 %+13.47%
13.81 %+25.73%
10.99 %+11.47%
9.86 %-36.28%
15.47 %+6.99%
14.46 %-11.27%
16.29 %-6.30%
17.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology, Inc. generates revenue through the sale of biotechnological services and products. The company offers cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series to customers in the domestic market. Preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing, are also provided as key revenue streams. Domestic market buyers primarily include research institutions and pharmaceutical companies seeking advanced biotech solutions. The firm's product portfolio targets the biotechnology and pharmaceutical sectors, with a focus on domestic customers. Cell culture series and molecular biology series are essential for laboratory research, while immune protein series supports immunological studies. Preclinical testing services cater to pharmaceutical firms requiring regulatory compliance for drug development. All products and services are distributed exclusively within the domestic market, ensuring focused market penetration and customer relationships. Level Biotechnology's revenue model relies on consistent demand for biotech products and testing services from domestic clients. The company's domestic market distribution strategy allows for tailored service delivery and strong client retention. By specializing in cell culture, molecular biology, and preclinical testing, Level Biotechnology maintains a competitive edge in the local biotech industry. Level Biotechnology is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Level Biotechnology's Return on Capital Employed (ROCE)

Level Biotechnology's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Level Biotechnology's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Level Biotechnology's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Level Biotechnology’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Level Biotechnology stock

Return on Capital Employed (ROCE) of Level Biotechnology is 14.40 % in 2025.

Return on Capital Employed (ROCE) of Level Biotechnology changed from 13.44 % to 14.40 %, representing a 7.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Level Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Level Biotechnology

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Level Biotechnology